The stock of Acadia Pharmaceuticals Inc (ACAD) has seen a -4.62% decrease in the past week, with a -10.13% drop in the past month, and a -3.72% decrease in the past quarter. The volatility ratio for the week is 2.58%, and the volatility levels for the past 30 days are at 3.17% for ACAD. The simple moving average for the last 20 days is -4.83% for ACAD stock, with a simple moving average of -3.33% for the last 200 days.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
The price-to-earnings ratio for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is 12.00x, which is above its average ratio. Moreover, the 36-month beta value for ACAD is 0.54. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 6 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ACAD is 165.49M and currently, short sellers hold a 8.72% of that float. On April 02, 2025, ACAD’s average trading volume was 2.36M shares.
ACAD) stock’s latest price update
The stock of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has decreased by -1.75 when compared to last closing price of 16.61. Despite this, the company has experienced a -4.62% fall in its stock price over the last five trading sessions. zacks.com reported 2025-03-28 that Acadia (ACAD) reported earnings 30 days ago. What’s next for the stock?
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Deutsche Bank repeating the rating for ACAD by listing it as a “Hold.” The predicted price for ACAD in the upcoming period, according to Deutsche Bank is $22 based on the research report published on February 11, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $20, previously predicting the price at $23. The rating they have provided for ACAD stocks is “Neutral” according to the report published on January 03rd, 2025.
ACAD Trading at -10.54% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.08% of loss for the given period.
Volatility was left at 3.17%, however, over the last 30 days, the volatility rate increased by 2.58%, as shares sank -10.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.11% lower at present.
During the last 5 trading sessions, ACAD fell by -4.62%, which changed the moving average for the period of 200-days by +6.18% in comparison to the 20-day moving average, which settled at $17.15. In addition, Acadia Pharmaceuticals Inc saw -11.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Kihara James, who sale 1,095 shares at the price of $17.05 back on Mar 26 ’25. After this action, Kihara James now owns 21,275 shares of Acadia Pharmaceuticals Inc, valued at $18,670 using the latest closing price.
Schneyer Mark C., the EVP, CHIEF FINANCIAL OFFICER of Acadia Pharmaceuticals Inc, sale 3,171 shares at $17.05 during a trade that took place back on Mar 26 ’25, which means that Schneyer Mark C. is holding 56,889 shares at $54,066 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.91 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.24. The total capital return value is set at 0.29. Equity return is now at value 38.89, with 23.39 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 3.03.
Currently, EBITDA for the company is 100.16 million with net debt to EBITDA at -2.74. When we switch over and look at the enterprise to sales, we see a ratio of 2.56. The receivables turnover for the company is 9.15for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.38.
Conclusion
To wrap up, the performance of Acadia Pharmaceuticals Inc (ACAD) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
